Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

NCT02112916 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02112916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02112916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 4, 2014
Completion date
September 16, 2026
Enrollment
847 (actual)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

adult t acute lymphoblastic leukemia, ann arbor stage ii adult lymphoblastic lymphoma, ann arbor stage ii childhood lymphoblastic lymphoma, ann arbor stage iii adult lymphoblastic lymphoma, ann arbor stage iii childhood lymphoblastic lymphoma, ann arbor stage iv adult lymphoblastic lymphoma, ann arbor stage iv childhood lymphoblastic lymphoma, childhood t acute lymphoblastic leukemia